<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-TRC-12003518</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2012-03-21</date_registration>
      <primary_sponsor>Military 302 hospital of China</primary_sponsor>
      <public_title>Clinic trial of combination therapy with Autologous hematopoietic stem cell transplantation and artificial liver system for the liver failure patients</public_title>
      <acronym />
      <scientific_title>Clinic trial of ombination therapy with Autologous hematopoietic stem cell transplantation and artificial liver system for the liver failure patients</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2012-05-31</date_enrolment>
      <type_enrolment />
      <target_size>1:20;2:20;3:20;</target_size>
      <recruitment_status>Completed</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=6042</url>
      <study_type>Interventional study</study_type>
      <study_design>Randomized parallel controlled trial</study_design>
      <phase>I (Phase I study)</phase>
      <hc_freetext>HBV-related acute-on-chronic liver failure</hc_freetext>
      <i_freetext>1:Routine supportive care +PBHSCT+PE  ;2:Routine supportive care +C-GSF ;3:Routine supportive care +PE  ;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Zhihong Wan</firstname>
        <middlename />
        <lastname />
        <address>100 Xisihuan Middle Road, Fengtai District, Beijing, China</address>
        <city />
        <country1 />
        <zip>100039</zip>
        <telephone>+86 010-66933434</telephone>
        <email>wan1011@yahoo.cn</email>
        <affiliation>Liver failure treatment and research center, Military 302 hospital of China</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Shaojie Xin</firstname>
        <middlename />
        <lastname />
        <address>100 Xisihuan Middle Road, Fengtai District, Beijing, China</address>
        <city />
        <country1 />
        <zip>100039</zip>
        <telephone>+86 010-66933434</telephone>
        <email>xsj302@yahoo.com.cn</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Signed the informed consent form before participation;
2. Between 18 and 65 years old;
3. Serum HBsAg (+);
4. chronic-on-acute liver failure;
5. Peripheral blood WBC&gt;3.0Ã—10^9/L.</inclusion_criteria>
      <agemin>18</agemin>
      <agemax>65</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. complicated with other virus infection (HAV, HCV, HDV, HEV, CMV, EBV and HIV);
2. Primary liver cancer;
3. Exists any other severe active physical or mental diseases, including uncontrolled clinically significant primary renal, cardiac, pulmonary, vascular, nervous, digestive, metabolic diseases, immune deficiency, and cancer;
4. Creatinine &gt; 133 umo1/L;
5. Existence of uncontrolled severe infection;
6. Shock;
7. Active gastrointestinal bleeding 8. Highly allergic to plasma, heparin, and protamine,</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Survial Time and Survival Rate;liver function indicators;PTA;Urea;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome />
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Military 302 hospital of China</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2012-01-11</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>